Search

Your search keyword '"Babjuk, Marek"' showing total 401 results

Search Constraints

Start Over You searched for: Author "Babjuk, Marek" Remove constraint Author: "Babjuk, Marek"
401 results on '"Babjuk, Marek"'

Search Results

2. Preoperative Plasma Insulin-Like Growth Factor-I and Its Binding Proteins-Based Risk Stratification of Patients Treated With Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma

3. En bloc resection of bladder tumour: the rebirth of past through reminiscence

6. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

7. Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels

8. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries

11. Comparative Outcomes of Primary Versus Recurrent High-risk Non–muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study

12. Preoperative plasma insulin-like growth factor-I and its binding proteins-based risk stratification of patients treated with radical nephroureterectomy for upper tract urothelial carcinoma

13. MP51-04 PROGNOSTIC VALUE OF INSULIN-LIKE GROWTH FACTOR-I AND ITS BINDING PROTEINS-BASED IN PATIENTS TREATED WITH RADICAL NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMA

14. MP38-07 INTERLEUKIN-6 AND ITS SOLUBLE RECEPTOR AS BLOOD-BASED BIOMARKERS PREDICTING DISEASE OUTCOMES AFTER RADICAL NEPHROURETERECTOMY IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA

15. MP38-06 PROGNOSTIC SIGNIFICANCE OF VCAM AND VEGF LEVELS PRIOR TO RADICAL NEPHROURETERECTOMY ON TREATMENT OUTCOMES

16. MP08-11 IMPACT OF PRE-SURGERY EGFR AND HER2 PLASMA LEVELS ON POST-SURGICAL OUTCOMES IN BLADDER CANCER PATIENTS RECEIVING RADICAL CYSTECTOMY

17. Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer

18. Clinical and molecular response to alpha1‐oleate treatment in patients with bladder cancer.

21. An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting

22. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees

25. Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex

26. Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non–muscle-invasive Bladder Cancer: Results of a European Survey

27. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group

30. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non–muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review

32. How to follow the new EU Council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration

34. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries

36. How to follow the new EU Council recommendation and improve prostate cancer early detection:the Prostaforum 2022 declaration

38. Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration

45. PD14-08 COMPARATIVE OUTCOMES OF PRIMARY AND RECURRENT HIGH GRADE NON-MUSCLE INVASIVE AND PRIMARY AND PROGRESSIVE MUSCLE-INVASIVE BLADDER CANCER AFTER RADICAL CYSTECTOMY: RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY

46. Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis, and Network Meta-Analysis with Focus on Different Energy Sources

47. Hemicorporectomy – the ultimate solution of terminal pelvic sepsis

48. COMPLICATION RATES AFTER RADICAL CYSTECTOMY AFTER RADIOTHERAPY: AN INTERNATIONAL, MULTICENTER RETROSPECTIVE STUDY ON 609 CASES: PD12-12

50. PD29-12 COMPARISON OF ONCOLOGICAL OUTCOMES OF DISTAL URETERAL ≤PT2 UROTHELIAL CARCINOMA MANAGED BY NEPHROURETERECTOMY, SEGMENTAL URETERECTOMY OR ENDOSCOPIC SURGERY

Catalog

Books, media, physical & digital resources